Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
about
Vaccines for preventing Japanese encephalitisPreparation and immunogenic properties of a recombinant West Nile subunit vaccineImmunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus MonkeysA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisJapanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4New Japanese encephalitis vaccines: alternatives to production in mouse brain.Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, doubleGenetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibodyCurrent use and development of vaccines for Japanese encephalitis.Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Duration of neutralizing antibody titer after Japanese encephalitis vaccination.Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test.Unique challenges faced by the clinical evaluation of dengue vaccines.Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice.Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013.Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules.
P2860
Q24243819-260FC5B6-9EF8-4878-B35A-D29695C58F49Q27478202-EDA9272B-B656-446C-A8FA-491D7DD17759Q27489620-E01AB541-8A06-463F-8496-31E3FC59F3A5Q28804076-AC5172DB-A760-4B6E-8376-C1CBDB0DCC8AQ33852635-8784FE71-E159-4E54-82D0-B568E75DC739Q34173039-FCD44141-D32A-4680-8D19-F1CA2603193FQ34976644-E53A399A-2E7C-42C5-B50E-98B6DF0432D5Q35140658-4B9FD3FF-5733-41F4-B12E-D0EA51E7918CQ36263779-D0822B64-9A15-4247-87CA-E03619A228E1Q36760059-AE3DABA5-9944-45F0-B158-FA06E9CE9423Q37032646-A2A81E1A-1E6B-4570-9054-B50CCC220AA2Q37842337-2AEBFC86-DD5D-40D3-A4AB-50E5291513D9Q39181962-BE6352AB-A80F-4D1F-A11B-65F5B370DAC2Q40202213-3D6639E1-EFB9-4778-AAEC-068F6D34AC75Q42232832-3D73D34F-A773-4B81-9661-05FCE2B1F505Q43034442-836256F1-19A9-4BC0-AFAA-474B44A8CE29Q45323668-ACECA239-3762-4577-A1CC-011834892530Q47263584-349A1D11-618B-4B1A-A9D9-ACAFBA1F7F0EQ47550067-1FD7D26B-890D-47DA-92EA-3D21A04DCC70Q50327490-002586D3-E39E-4096-AD41-4DAEA6D08AAEQ51733262-1709D1B0-F7CB-4930-B991-F0B55046032FQ54079810-8C9E5D33-04C8-4A2C-B6B1-0FDD39ECDEA9Q55468883-11F6E7A3-5DEF-47F4-B576-4EF8966041AA
P2860
Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Points to consider in the deve ...... e encephalitis virus vaccines.
@ast
Points to consider in the deve ...... e encephalitis virus vaccines.
@en
type
label
Points to consider in the deve ...... e encephalitis virus vaccines.
@ast
Points to consider in the deve ...... e encephalitis virus vaccines.
@en
prefLabel
Points to consider in the deve ...... e encephalitis virus vaccines.
@ast
Points to consider in the deve ...... e encephalitis virus vaccines.
@en
P1433
P1476
Points to consider in the deve ...... e encephalitis virus vaccines.
@en
P2093
P356
10.1016/S0264-410X(00)00038-4
P407
P478
18 Suppl 2
P577
2000-05-01T00:00:00Z